SC 13D/A 1 a2054480zsc13da.txt SCHEDULE 13D/A ---------------------------- OMB APPROVAL ---------------------------- OMB Number: 3235-0145 Expires: August 31, 1999 Estimated Average Burden Hours per response .. 14.90 ---------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Rule 13d-101 Information to be Included in Statements Filed pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) (AMENDMENT NO. 5) PHARMACEUTICAL RESOURCES, INC. --------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE --------------------------------------------------------------------- (Title of Class of Securities) 717125 10 8 --------------------------------------------------------------------- (CUSIP Number) NITZA EINAN, ADV. CLAL INDUSTRIES AND INVESTMENTS LTD. 3 AZRIELI CENTER, TRIANGLE TOWER TEL AVIV, 67023 TEL: 972-3-6075795 ISRAEL --------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) JUNE 5, 2001 --------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box |_| NOTE: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 27 pages SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 2 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Clal Biotechnology Industries Ltd. (no U.S. I.D. number) ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 3 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Clal Industries and Investments Ltd. (no U.S. I.D. number) ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 4 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS IDB Development Corporation Ltd. (no U.S. I.D. number) ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 5 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS IDB Holding Corporation Ltd. (no U.S. I.D. number) ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 6 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Leon Recanati ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 7 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Oudi Recanati ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 8 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Judith Yovel Recanati ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 9 OF 27 PAGES ------------------------- ----------------------- ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Elaine Recanati ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / ------------------------------------------------------------------------------- (3) SEC USE ONLY ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION United States ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. This Amendment No. 5 amends items 2 and 5 of this Statement on Schedule 13D, as previously filed with the Securities and Exchange Commission. Unless otherwise defined in this Amendment No. 5 to Schedule 13D, capitalized terms have the meanings given them in the Schedule 13D as previously filed. Item 2. IDENTITY AND BACKGROUND (a) (b) and (c): On May 28, 1999, Mr. Raphael Recanati died and ceased to be a Reporting Person. Mr. Raphael Recanati's son, Mr. Oudi Recanati, whose address is Quai de L'Ile 3, CH-1204, Geneva, Switzerland, is hereby added as a Reporting Person. Mr. Oudi Recanati's present principal occupation is Chairman, Discount Bank and Trust Company, Geneva, Switzerland. On July 13, 2000, Clal (Israel) Ltd. merged into IDB Development and ceased to be a Reporting Person. Clal Pharm changed its name from Clal Pharmaceutical Industries Ltd. to Clal Biotechnology Industries Ltd. on June 18, 1998. The address of Clal Industries, Clal Pharm, IDB Development and IDB Holding is 3 Azrieli Center, Triangle Tower, Tel Aviv 67023, Israel. As of June 29, 2001, IDB Development owned 71.14% of Clal Industries. As of June 29, 2001, IDB Holding owned 56.4% of IDB Development. Mr. Leon Recanati and Mrs. Judith Yovel Recanati are brother and sister and Mr. Oudi Recanati is their cousin. They are the nephews and niece of Mrs. Elaine Recanati. As of June 29, 2001, companies controlled by Oudi Recanati, Leon Recanati, Judith Yovel Recanati and Elaine Recanati held in the aggregate approximately 51.7% of the voting power and equity of IDB Holding. The name, citizenship, residence or business address, present principal occupation, and the name, principal business and address of each corporation in which such occupation is conducted of each of the executive officers and directors of Clal Industries, Clal Pharm, IDB Holding and IDB Development are set forth on Exhibits 1, 2, 3 and 4 hereof, respectively, and incorporated herein by reference. (d) None of the Reporting Persons has, during the past five years, been convicted in any criminal proceeding, excluding traffic violations and similar misdemeanors. Page 10 of 27 pages (e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. (f) Mr. Oudi Recanati is a citizen of Israel. Item 5. INTEREST IN SECURITIES OF THE ISSUER On July 1, 1998, Clal Pharm sold 1,813,272 shares of Common Stock of the Issuer to Merck at a price of $2 per share, in accordance with the Stock Purchase Agreement, leaving a balance of 500,000 shares of Common Stock owned by Clal Pharm. On June 5, 2001, the Issuer, Merck and Clal Pharm entered into an agreement amending the Stock Purchase Agreement to permit Clal Pharm to immediately sell all of its shares of Common Stock. From June 11, 2001 through June 29, 2001, Clal Pharm sold all of its remaining 500,000 shares of Common Stock of the Issuer. As of June 29, 2001, Clal Pharm, Clal Industries, IDB Holding, IDB Development and the Reporting Persons who are natural persons no longer hold beneficially or of record shares of Common Stock of the Issuer. The following table sets forth the sales of shares of Common Stock made by Clal Pharm from June 11, 2001 through June 29, 2001. All such sales were made in the New York Stock Exchange:
================================================== NO. OF SHARES PRICE PER DATE SOLD SHARE US$ -------------------------------------------------- 11 June 2001 20,000 24.300 12 June 2001 10,000 24.400 12 June 2001 10,000 24.300 13 June 2001 9,800 24.250 13 June 2001 10,000 24.300 13 June 2001 30,000 24.350 13 June 2001 200 24.650 14 June 2001 1,300 24.400 15 June 2001 20,400 24.232 18 June 2001 11,500 24.000 20 June 2001 2,000 23.190 20 June 2001 4,000 23.180 20 June 2001 2,000 23.200 20 June 2001 4,000 23.220 21 June 2001 40,000 24.100 --------------------------------------------------
Page 11 of 27 pages
================================================== NO. OF SHARES PRICE PER DATE SOLD SHARE US$ -------------------------------------------------- 21 June 2001 60,000 24.200 21 June 2001 5,700 24.240 21 June 2001 5,000 24.250 21 June 2001 1,000 24.300 21 June 2001 900 24.350 22 June 2001 25,000 24.200 22 June 2001 2,100 24.250 25 June 2001 20,000 24.650 25 June 2001 20,000 24.600 25 June 2001 700 24.190 25 June 2001 1,200 24.170 25 June 2001 400 24.160 25 June 2001 900 24.150 25 June 2001 20,000 24.050 26 June 2001 16,200 24.200 26 June 2001 200 24.210 26 June 2001 5,100 24.220 26 June 2001 3,300 24.230 26 June 2001 7,100 24.240 26 June 2001 13,800 24.250 26 June 2001 600 24.270 26 June 2001 300 24.300 26 June 2001 9,300 24.340 26 June 2001 1,000 24.350 27 June 2001 20,000 24.150 27 June 2001 13,000 24.200 27 June 2001 200 24.220 27 June 2001 3,300 24.230 27 June 2001 20,000 24.280 27 June 2001 3,500 24.300 27 June 2001 10,000 24.500 27 June 2001 2,800 24.800 27 June 2001 900 24.850 27 June 2001 1,100 24.900 27 June 2001 200 24.960 27 June 2001 300 24.980 27 June 2001 4,700 25.000 27 June 2001 5,000 25.800 27 June 2001 2,400 26.320 27 June 2001 2,100 26.340 27 June 2001 500 26.350 29 June 2001 2,000 27.050 29 June 2001 3,000 27.250 29 June 2001 2,000 27.350 -------------------------------------------------
Page 12 of 27 pages
================================================== NO. OF SHARES PRICE PER DATE SOLD SHARE US$ -------------------------------------------------- 29 June 2001 2,000 27.500 29 June 2001 900 27.750 29 June 2001 100 27.900 29 June 2001 1,000 28.090 29 June 2001 1,000 28.500 29 June 2001 1,000 29.000 29 June 2001 200 29.270 29 June 2001 300 29.390 29 June 2001 500 30.000 29 June 2001 500 30.020 29 June 2001 500 31.000 --------------------------------------------------
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS Exhibits 1, 2, 3 and 4 Name, citizenship, business address, present principal occupation and employer of executive officers and directors of (1) Clal Industries, (2) Clal Pharm, (3) IDB Holding and (4) IDB Development Exhibit 5 Agreement dated December, 15, 1999, between Oudi Recanati and IDB Holding authorizing IDB Holding to file this Schedule 13D and any amendment hereto on behalf of Mr. Recanati. Exhibit 6 Agreement dated June 5, 2001, among the Issuer, Merck and Clal Pharm. Page 13 of 27 pages SIGNATURE After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. Dated: July 18, 2001 CLAL BIOTECHNOLOGY INDUSTRIES LTD. CLAL INDUSTRIES AND INVESTMENTS LTD. IDB DEVELOPMENT CORPORATION LTD. IDB HOLDING CORPORATION LTD. LEON RECANATI OUDI RECANATI JUDITH YOVEL RECANATI ELAINE RECANATI By: IDB HOLDING CORPORATION LTD. By: /s/ James I. Edelson ----------------------------------------------------- James I. Edelson, U.S. Resident Secretary of IDB Holding Corporation Ltd. for itself and on behalf of (i) Clal Biotechnology Industries Ltd., Clal Industries and Investments Ltd., IDB Development Corporation Ltd., Elaine Recanati, Leon Recanati and Judith Yovel Recanati pursuant to the agreements annexed to Amendment No. 4 to the Schedule 13D as exhibits 9-10, 12 and 14-16, as filed and (ii) Oudi Recanati pursuant to the agreement annexed to this Amendment No. 5 to the Schedule 13D as exhibit 5, as filed. Page 14 of 27 pages